<DOC>
	<DOCNO>NCT00919113</DOCNO>
	<brief_summary>A new device interstitial cystitis compare inactive control determine safe effective . The study last approximately 7 week 19-week follow-up period .</brief_summary>
	<brief_title>Efficacy Safety Study Uracyst Treat Interstitial Cystitis/Painful Bladder Syndrome</brief_title>
	<detailed_description>Multi-center , randomize , double-blind , parallel , 8 weekly instillation 7-week period post-treatment follow-up additional 19 week total study length 26 week .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Pain</mesh_term>
	<mesh_term>Cystitis</mesh_term>
	<mesh_term>Cystitis , Interstitial</mesh_term>
	<criteria>Are female , 18 year old Have diagnose IC/PBS Are willing provide write informed consent authorization disclose fully inform risk participation Are lactate female Have previously receive investigational product device within 30 day screen Have previously receive Uracyst Are currently receive therapy InterstimÂ® Have condition/disease , opinion investigator , could compromise subject safety confound interpretation study result Are unable unwilling comply protocol requirement</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Bladder Pain</keyword>
	<keyword>GAG replacement therapy</keyword>
	<keyword>IC/PBS</keyword>
</DOC>